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Cumhur İbrahim Başsorgun3, Hilmi Önder Okay4 and Münir Demirci5Abstract
Introduction: Ameloblastoma is a benign but locally aggressive tumor of odontogenic epithelial tissue. Reports of
radiotherapy treatment modalities are limited in the literature.
Case presentation: A thirty-five year old male presented with complaints of headache radiating to his face for
about six months and impaired vision. The patient’s Positron Emission Tomography (PET) showed a mass in the left
maxillary sinus extending to the nasal cavity and invading the adjacent tissues. An R2 (macroscopic residual tumor)
surgical resection performed to debulk the tumor. Due to the recurrence and residual mass, the patient was treated
with helical tomotherapy. At 2 months post-radiotherapy, patient’s vision returned to normal. PET scan showed a
significant reduction in lesion size 12 months post-radiation.
Conclusion: In cases of ameloblastic carcinoma with, post-surgical recurrence or patients not suitable for surgical
treatment, helical tomotherapy can be an effective treatment option.
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Ameloblastoma is a locally aggressive benign tumor de-
rived from the odontogenic epithelial tissues [1]. The
tumor has a slight increased preponderance in females
and is mainly diagnosed in the third or fourth decade of
life [2,3]. It accounts for about 1% of all jaw tumors [4].
Ameloblastoma prevalently occurs in the ramus and the
angulus of the mandible, and rarely in the maxilla [5].
While often clinically asymptomatic, the tumor is usually
spotted with bone expansion or detected in routine
radiological studies [6]. Numerous histological types
have been reported based on the histological findings
[7]. The most recent WHO classification has categorized
ameloblastoma, to malignant ameloblastoma and amelo-
blastic carcinoma. Malignant ameloblastoma is differ-
ent from ameloblastoma since metastases may occur in
the former. Both have benign histology. Ameloblastic* Correspondence: timurkoca3@gmail.com
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less of the metastasis occurrence. In ameloblastoma,
metastasis rarely occurs [8].
The basic form of treatment for localized ameloblas-
toma is radical surgery. The only treatment option in
metastatic disease appears to be chemotherapy, although
the outcome is not favorable. Radiotherapy modalities
are limited in the literature [9].
Here we report a case of ameloblastic carcinoma with
basal cell histology, where helical tomotherapy achieved
a prominent response.Case
A thirty-five year old male presented with complaints of
headache radiating to his face for about six months and
impaired vision. He presented to an outpatient of Ear,
Nose and Throat clinic in April 2012. The Magnetic
Resonance Imaging (MRI) and Positron Emission
Tomography (PET) images (Figure 1) shows a tumor
extending to the sphenoidal sinus from the anterior
segment of the sphenoid bone. The tumor invades thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pre-treatment Positron Emission Tomography (PET) images of the case patient.
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retro-orbital areas, almost completely invading the left
maxillary sinus and extending to the nasal cavity. The
mass was observed to displace optic nerves bilaterally.
The tumor size was measured at 57 × 56 × 63 mm.
Post-contrast series demonstrated intense and hetero-
geneous contrast enhancement. Based on the biopsy
findings, the patient was diagnosed with ameloblastic
carcinoma with basaloid appearance (Figure 2). The
patient underwent surgery in the Neurosurgery Clinic
in May 2012. Due to the size of the mass and proximity
to critical organs, only R2 (macroscopic residual tumor)
resection could be performed. The patient developed post-
operative infection, and was treated with appropriate anti-
biotic therapy, which failed to treat the infection. Thepatient was operated again in June 2012. After the recovery
from infection, due to the recurrent and residual mass, the
multi-disciplinary oncology council decided to consult with
the Radiation Oncology Clinic for post-operative external
radiotherapy. The visual field examination The visual as-
sessment conducted by the Eye Diseases Clinic before the
initiation of external radiotherapy revealed bilateral visual
impairment and diplopia. Serial tomographic sections were
taken for the purpose of contouring in radiation therapy
plan. The sections were transmitted to the contouring work
station through Digital Imaging and Communications in
Medicine (DICOM), and Reconstructive Digital Radiog-
raphy (DRR) was obtained. The DRR contouring of the pa-
tient was performed using a Tomocon (TetramedTM,
Slovak republic) contouring workstation. The patient’s eyes,
Figure 2 Ameloblastic carcinoma with basaloid appearance.
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glands, spinal cord, cochleae, vestibules and skin were con-
toured as critical organs. Prior to the radiotherapy for ame-
loblastic carcinoma, two separate clinical target volumes
(CTV) were defined. CTV1 was defined by adding a 5 mm
margin to the gross tumor volume, while planning target
volume (PTV) 1 was obtained by adding a 3 mm margin to
the CTV1 volume, and then administration of 60 Gy total
dose was planned using simultaneous integrated boost
(SIB) technique. PTV2 was defined by adding a 15 mm
margin to CTV1 volume, and the prescription dose was 50
Gy to PTV2 (Table 1). The patient’s treatment plan was de-
signed with the Tomotherapy planning system (Accuray
Inc., Madison, USA). With this planning system, the appro-
priate prescription doses for organs at risk (OAR) were de-
fined, and routine quality assurance for the prescribed
doses was conducted to prepare the patient for the treat-
ment. Related to metastases and close proximity of OAR’s
to PTV’s, some of the OAR dose objectives were slightly
exceeded Quantec recommendations. The patient was in-
formed about the treatment related adverse effects and
informed consent was signed before the start of the treat-
ment session. Prior to each session of treatment, daily Mega
Voltage Computerized Tomography (MVCT) scans were
performed, and these were compared with the images of
treatment planning to achieve set-up accuracy.Table 1 Dosimetric Parameters of PTV60 (SIB) and PTV54
Variable Dmax (Gy) Dmean (Gy) Dmin (Gy) HI CI
PTV60 64.72 61.38 47.44 0.08 0.78
PTV54 64.72 60.45 24.61 0.28 0.82
Abreviations: Dmax maximum dose, Dmean mean dose, Dmin Minimum dose,
PTV planned target volume, HI Homogenity index, CI Conformity index.The MR images taken at 2 months after radiotherapy
showed partial regression in lesion size. Complete clin-
ical remission was achieved in patient’s bilateral visual
impairment and diplopia during follow-up. The PET
scan taken at 12 months after radiotherapy demon-
strated regression of the tumor in the left maxillary
sinus, which reduced to 3 × 3.5 × 3 cm, and 18F-fluoro-
2-deoxy-D-glucose (FDG) uptake decreased (Previous
SUD: 25.36; Current SUD 5.33), while a complete re-
sponse was achieved in the lesion intracranial extensions
(Figure 3). The brain MRI detected no pathological
contrast involvement in this area. The patient is under
ongoing follow-up. He has not reported any complaints
in the check-up conducted in January 2014.
Discussion
Although the term ‘ameloblastoma’ was coined by
Churchill in 1933, the first detailed description of this
lesion was given by Falkson in 1879 [3]. While known
as benign odontogenic tumors, ameloblastomas are
slow-growing tumors with a high recurrence rate and
tendency for local invasion, expansion and destruction
in the bone [10-12]. Dental caries, trauma, infection,
inflammation, dental disorders, malnutrition and viral
pathogens have been suggested to play a role in the eti-
ology [13]. The most common symptom is a slow-
growing painless swelling, and less frequently, dental
malocclusion, pain, paresthesia or anesthesia might
occur. In rare cases, pain may be experienced espe-
cially when the tumor is infected, but it causes no
symptoms unless there is nerve involvement [6,14].
In 80% of the cases, ameloblastoma originates in the
mandible. It mainly involves the angulus and ramus re-
gions of the mandible (70% of cases), whereas 20% of
the all cases it involves the premolar region, and 10%
the anterior region [2,5,15].
According to the histological findings, the tumors
are classified as follicular, plexiform, acanthomatous,
granular, basal cell and desmoplastic type [7]. The
main clinicoradiographic types of ameloblastoma have
been defined as conventional solid or multicystic
intraosseous, well-defined unicystic (intraosseous) and
peripheral (extraosseous) [10,11,16].
In the diagnosis of ameloblastoma, the radiological
tools such as panoramic radiography, CT, MRI and PET-
CT can be used. Panoramic radiography is often used in
daily practice, while the other methods are better at de-
tecting the presence of metastases, contours, content
and soft tissue extension of the lesion [4,5,17,18].
Although considered a benign tumor, ameloblastoma
may develop recurrence after resection and become clin-
ically more aggressive, while leading to massive local
destruction and metastasis [7]. 15-25% of the cases de-
velop recurrence after radical surgery, while conservative
Figure 3 Positron Emission Tomography (PET) images of the patient after external radiotherapy.
Koca et al. Radiation Oncology 2014, 9:157 Page 4 of 5
http://www.ro-journal.com/content/9/1/157surgery recurrence rate is 75-90% [19]. In patients allowing
radical surgery, despite controversies, 1–2 cm margin is
sufficient as it significantly decreases the recurrence rate
[2]. Since there is always risk of recurrence, even 25–30
years after the primary treatment, patients should be moni-
tored for a long time [3]. Its metastatic spread incidence
has been reported as 1 to 4.5% of all cases [2]. Even
though rare, cases with metastases to lungs, pleura,
spleen, kidney, heart, skull, spine, brain, and lymph
nodes have been reported [11]. Surgery may be an
option in the presence of metastases. A review of the
current literature reveals that various chemotherapeutic
agents have been used, including cisplatin, cyclophospha-
mide, carboplatin, paclitaxel, doxorubicin, methotrexate,
prednisone, bleomycin, 5-fluorouracil and dacarbazine, andvarying degrees of responses have been reported for each
agent [8,20].
As ameloblastoma is a rare and slow-growing tumor,
the use of radiotherapy in the treatment should be
discussed. Also there are limited data for detailed
radiotherapy field design and dose prescriptions. The
information regarding radiosensitivity in the current
literature is ambiguous [9]. In incomplete resection
cases, adjuvant radiotherapy may be considered a
treatment option [8,21]. The current studies found in
the literature fail to provide sufficient information on
the use of radiotherapy/chemoradiotherapy in meta-
static disease [8]. Besides, the use of radiotherapy
might increase the incidence of conventional bone
complications, osteonecrosis and bone carcinoma [9].
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such complications are tried to be minimized. However,
there has been no research examining the use of helical
tomotherapy in the treatment of ameloblastoma.
Conclusion
Ameloblastoma is a slow-growing tumor with no standard
chemotherapy treatment options, and primarily treated
with curative surgical procedure. In conclusion, we suggest
that helical tomotherapy can provide an effective treatment
option in ameloblastoma cases where complete resection is
not feasible or in patients developing local recurrence.
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